Methods of identifying compounds useful for treating autoimmune

Details Methods of identifying compounds useful for treating autoimmune Methods of identifying compounds useful for treating autoimmune

1994-08-24

1997-09-30

Saunders, David

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving nucleic acid

435 724, 435 78, 435 29, 4351723, 436501, 530358, 536 235, C07H 2100, C07K 14705, C12Q 168, G01N 33566

Patent

active

056724730

ABSTRACT:
Disclosed are methods of identifying compounds which inhibit transcription activation by CIITA and thus inhibit MHC class II gene expression. Such compounds can affect the induction of an immune response. The methods employ, independently, the activation and interactions domains of CIITA. The methods also employ the activation and interaction domains of isotype-specific CIITA proteins, allowing for the identification of compounds which are isotype-specific inhibitors of transcription and which are useful for selectively affecting the immune system.

REFERENCES:
Begovich A.B. et al.; "A Specific HLA-DP.beta. Allele is Associated With Pauciarticular Juvenile Rheumatoid Arthritis But Not Adult Rheumatoid Arthritis"; Proc. Natl. Acad. Sci. USA 86:9489-9493 (1989).
Gyuris J. et al.; "Cdi1, A Human G1 and S Phase Protein Phosphatase That Associates With Cdk2"; Cell 75:791-803 (1993).
Keegan L. et al.; "Separation of DNA Binding from the Transcription-Activating Function of a Eukaryotic Regulatory Protein"; Science 231:699-703 (1986).
Lin Y. et al.; "GAL4 Derivatives Function Alone and Synergistically with Mammalian Activators In Vitro"; Cell 54:659-664 (1988).
Lin Y. et al.; "Mechanism of Action of Acidic Transcriptional Activator In Vitro"; Cell 64:971-981 (1991).
Ma J. et al.; "Converting a Eukaryotic Transcriptional Inhibitor into an Activator"; Cell 55:443-446 (1988).
Ma J. et al.; "Deletion Analysis of GAL4 Defines Two Transcriptional Activating Segments"; Cell 48:847-853 (1987).
McDermott M. et al.; "The Immunogenetics of Rheumatic Diseases"; Bulletin on the Rheumatic Diseases 38:1-10 (1988).
Ono S.J. et al.; "An Isotype-Specific Trans-Acting Factor Is Defective in a Mutant B Cell Line That Expresses HLA-DQ But Not -DR or -DP"; J. Exp. Med. 173:629-637 (1991).
Roberts S.G.E. et al.; "Interaction Between an Acidic Activator and Transcription Factor TFIIB is Required for Transcriptional Activation"; Nature 363:741-744 (1993).
Sadowski I. et al.; "GAL4-VP16 is an Unusually Potent Transcriptional Activator"; Nature 335:563-564 (1988).
Scharf S.J. et al.; "Specific HLA-DQB and HLA-DRB1 Alleles Confer Susceptibility to Pemphigus Vulgaris"; Proc. Natl. Acad. Sci. USA 86:6215-6219 (1989).
Steimle V. et al.; "Complementation Cloning of an MHC Class II Transactivator Mutated in Hereditary MHC Class II Deficiency (or Bare Lymphocyte Syndrome)"; Cell 75:135-146 (1993).
Zervos A.S. et al., "Mxi1, A Protein That Specifically Interacts with Max to Bind Myc-Max Recognition Sites"; Cell 72:223-232 (1993).
R. Lewin, Science, 237, 1570 (1987).

Affiliated with

Also associated with

Rating

Methods of identifying compounds useful for treating autoimmune does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods of identifying compounds useful for treating autoimmune , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of identifying compounds useful for treating autoimmune will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2255917